Efficacy of Remdesivir for COVID-19

Hongming Zhang; Jibei Chen; Xiyong Wang; Baoan Chen

Efficacy of Remdesivir for COVID-19

Discov Med. 2021 Mar-Apr;31(163):57-60.

Authors

Hongming Zhang¹, Jibei Chen¹, Xiyong Wang^{2

3}, Baoan Chen^{4

3}

Affiliations

¹ Department of Respiratory Medicine, Yancheng Third People's Hospital, the Affiliated Yancheng Hospital of Southeast University Medical College, Yancheng, Jiangsu 224001, China.
² Department of Oncology, Suzhou Hospital of Anhui Medical University (Suzhou Municipal Hospital of Anhui Province), Suzhou, Anhui 234000, China.
³ Corresponding author.
⁴ Department of Hematology and Oncology, Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu 210009, China.

PMID: 34965372

Abstract

Remdesivir is a broad-spectrum antiviral agent. With the rapid spread of Coronavirus disease 2019 (COVID-19) globally, remdesivir is taking the spotlight for COVID-19 treatment. Despite the promising signs of anti-CoV activity in several preclinical and clinical studies, more data of remdesivir in the treatment of COVID-19 is still needed for evaluating its efficacy.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adenosine Monophosphate / analogs & derivatives
Alanine / analogs & derivatives
Antiviral Agents / therapeutic use
COVID-19 Drug Treatment*
Humans
SARS-CoV-2

Substances

Antiviral Agents
remdesivir
Adenosine Monophosphate
Alanine